tiprankstipranks
ImmuPharma Appoints New Auditor, Crowe LLP
Company Announcements

ImmuPharma Appoints New Auditor, Crowe LLP

Story Highlights

Don't Miss Our Christmas Offers:

ImmuPharma ( (GB:IMM) ) has shared an announcement.

ImmuPharma PLC has announced the appointment of Crowe LLP as its new auditor, replacing CLA Evelyn Partners Limited. This change is effective immediately and Crowe will audit the company’s financial statements for the year ending December 31, 2024. A proposal for Crowe’s reappointment will be presented at the 2025 Annual General Meeting, highlighting a strategic shift in the company’s financial operations. This move could impact the company’s industry positioning by potentially enhancing financial oversight and transparency to its stakeholders.

More about ImmuPharma

ImmuPharma PLC is a specialty biopharmaceutical company focusing on the discovery and development of peptide-based therapeutics. It has a portfolio that includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The company’s lead program, P140, is aimed at treating Systemic Lupus Erythematosus and Chronic Idiopathic Demyelinating Polyneuropathy, with potential activity for other autoimmune diseases.

YTD Price Performance: -28.31%

Average Trading Volume: 1,423,547

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: £4.98M

Find detailed analytics on IMM stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskImmuPharma Appoints New Auditor Crowe LLP
TipRanks UK Auto-Generated NewsdeskImmupharma Announces Change in Major Shareholdings
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App